On the other hand, a larger percentage of patients in the NAFLD/NASH group started lenvatinib at a reduced dose (36.9% vs. 26.0%, P = 0.037), while there was no significant difference observed in regard to hepatic function (Child–Pugh score, ALBI score, mALBI grade), tumor burden (TNM-LCSGJ, BCLC stage), or malignancy grade of HCC (elevated AFP: ≥ 400 ng/mL) between them (Table 2). Here, AFP is linked to hepatocellular carcinoma.